Lumida
/BTMD
⌘K
Biote Corp

Biote Corp

BTMD
$1.33USD+1.53%+0.02 today

MARKET CAP

47.8M

P/E (TTM)

3.0x

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$4

AI Summary

Stalk
TrimMedium

Price remains in a medium- and long-term downtrend following an early-August support failure, and despite extreme oversold readings, the structural bias favors bearish execution. Selling on a rebound into the broken support zone or moving averages (around $1.47–$1.56) aligns with resistance rejection. Defer outright selling now and wait for a minor rally into key resistance to trim positions.

  • Product recall resolved; production and margins to normalize by H2 2026.
  • Insider buying: Exec chairman acquired ~131,950 shares for $202K.
  • Q2 2026 net loss $0.23/sh versus $0.03 profit expected.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$165.0M$185.4M$197.2M$192.2M
YoY %+12.4%+6.4%-2.5%
P / Sales0.2x0.7x1.1x0.5x
EV / Sales0.7x1.2x2.0x1.2x
Gross Profit, Adj.$110.4M$127.5M$139.1M$137.4M
YoY %+15.5%+9.1%-1.2%
Margin %66.9%68.8%70.5%71.5%
EV / Gross Profit1.0x1.8x2.9x1.7x
EBITDA, Adj.$-58.5M$31.7M$35.2M$39.2M
YoY %+154.1%+11.2%+11.5%
Margin %-35.5%17.1%17.8%20.4%
EV / EBITDA-2.0x7.1x11.3x5.8x
EBIT$-60.7M$28.7M$31.6M$35.6M
YoY %+147.2%+10.3%+12.5%
Margin %-36.8%15.5%16.0%18.5%
EV / EBIT-1.9x7.8x12.6x6.4x
Net Income$-969,000$3.3M$3.2M$27.0M
YoY %+442.2%-4.8%+756.7%
Net Margin-0.6%1.8%1.6%14.1%
EPS (GAAP)-$0.12$0.13$0.09$0.74
YoY %+208.3%-30.8%+722.2%